ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

The IDeate-Lung01 trial showed a 48% confirmed response rate with Merck’s B7-H3 directed antibody-drug conjugate in previously treated extensive-stage small cell lung cancer, with durable benefit ...

Interim results from the ongoing Phase IV LOTUS trial showed that Daybue delivered sustained behavioral improvements and ...

In this week’s Applied Clinical Trials Brief, we recap three top stories: Novo Nordisk’s stepwise approach to AI adoption, ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

Results from the Phase III STRIDE-13 trial (NCT06177912) showed that Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) demonstrated robust immune responses in children and adolescents aged ...

The FDA-approved therapy is now included in National Comprehensive Cancer Network clinical guidelines as a treatment option ...

Results from a Phase II trial (NCT06449209) showed that BioNTech’s and Bristol Myers Squibb’s pumitamig in combination with ...

Five-year results from the Phase III EMPOWER-Lung 3 trial show Libtayo combined with chemotherapy achieved a 19.4% overall ...

In this episode of the Applied Clinical Trials Brief, Shipra Patel, global therapeutic area section head for endocrinology ...